Story

Veeva Systems Stock Surges on Earnings Beat and Raised Full-Year Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 27, 20262 min read
Veeva Systems Stock Surges on Earnings Beat and Raised Full-Year Guidance
Text size
Background

Veeva Systems (VEEV) stock surged 7.8% in pre-market trading after the cloud software provider for the life sciences industry announced fiscal second-quarter results that surpassed Wall Street expectations and raised its full-year forecast.

Strong Quarterly Results

Veeva reported significant year-over-year growth, driven by strong demand for its core products. The company's performance topped analyst consensus on both revenue and earnings for the quarter.

  • Q2 Revenue: $928 million, an 18% increase year-over-year, beating the consensus estimate of approximately $905 million.
  • Q2 Adjusted EPS: $2.35, well ahead of the Street's expectation of $2.22.
  • Subscription Revenue: A key metric for the company, this segment grew 16% to $766.8 million.

CEO Peter Gassner noted that the company's "Vault CRM had its best quarter ever," and said artificial intelligence is "opening up the next big chapter for Veeva and life sciences." The company also maintained strong profitability, with non-GAAP operating margins holding firm above 44%.

Upgraded Outlook and Key Customer Wins

Sample IUX Markets – In-articleAd

Following the strong quarter, Veeva management provided an optimistic outlook for the remainder of fiscal year 2027, lifting its guidance above prior analyst projections.

  • Full-Year Revenue Guidance: Raised to a range of $3.68–$3.69 billion, from a consensus of about $3.65 billion.
  • Full-Year Adjusted EPS Outlook: Lifted to $9.21 from a previous forecast of $9.05.

The company also highlighted significant new business, announcing that top-20 biopharmaceutical firms Eli Lilly and Biogen have committed to its Vault CRM platform. This brings the total to 12 of the industry's 20 largest companies using the service.

Analyst Confidence Rises

Wall Street analysts responded positively to the report, with several firms upgrading their price targets. Barclays raised its target on Veeva to $315 from $275, maintaining an Overweight rating. In a separate note, Piper Sandler initiated coverage with an Overweight rating and a $295 price target, signaling fresh confidence in the stock's growth trajectory.

Read next

More on Stocks
Back to latest news

LATEST